The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Status:
Terminated
Trial end date:
2019-08-05
Target enrollment:
Participant gender:
Summary
This is a 28-week, multi-center, randomized, double-blind, placebo-controlled trial to study
a potential synergistic effect of Dapagliflozin plus Exenatide once-weekly in combination
with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant
patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c≥8.0% and
≤ 11.0%).